RE:RE:RE:AA ?OK ... it confirmed it.
And by virtue of the Bracelet-1 results the study results went on to interpretedly confirm that pelareorep + paclitaxel + atezolizumab was effective in advanced or metastatic pancreatic cancer AND that this combination would very likely be effective in metastatic breast cancer since atezolizumab is a PD-L1 blocker that has its Fc component silenced. Unlike Avelumab, a PD-L1 inhibitor, which was used in the pelareorep + paclitaxel + Avelumab cohort of the Phase 2 Bracelet-1 clinical study, the PD-L1 inhibitor atezolizumab has its Fc protein component silenced and is synergistic in combination with pelareorep.
https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-updated-randomized-phase-2-data-from-bracelet-1-metastatic-breast-cancer-trial-that-show-pelareorep-driving-robust-increases-in-progression-free-survival-and-confirmed-overall-response-rate-301842058.html